NSCаâInstitute of CardiologyâанаKievанаUkraine,. Topic(s):. Acute Heart FailureаâаEpidemiology, Prognosis, Outcome. Citation: Background: The prevalence ...
Abstract: P1153 Acute heart failure in patients with STsegment elevation myocardial infarction: prognostic significance of midrange left ventricular ejection fraction Authors: S Kozhukhov1, A Parkhomenko1, N Dovganych1, 1NSC “Institute of Cardiology” Kiev Ukraine, Topic(s): Acute Heart Failure – Epidemiology, Prognosis, Outcome Citation: Background: The prevalence and clinical outcomes of acute heart failure (AHF) with midrange left ventricular ejection fraction (mrEF) after STelevation myocardial infarction (STEMI) have not been well elucidated. According to the new European Society of Cardiology guidelines we allocated AHF patients (mrEF; 40% to 49%) as a distinct group. Objective: To analyze the prevalence of AHF, clinical profile, inhospital outcomes and and longterm survival of STEMI patients with mrEF. Methods: We conducted a retrospective study of 606 consecutive patients with STEMI (age 54.1±0.4 years) hospitalized within 12 hours of symptoms onset (4.1±0.2 hours), who had echocardiographic examination performed on admission. Based on sign and symptoms of AHF (Killip IIIII) within 24 hours patients were divided into two groups: with AHF 171 and without AHF 435 patients. Main outcome was cardiovascular mortality with a median followup of 3 years. Results: Patients with AHF were likely to be older, have history of ischaemic heart disease and previous MI. On admission AHF patients presented higher level of glycemia and Creactive protein, lower glomerular filtration rate in compare to patients without AHF. During inhospital stay AHF patients had significantly higher rate of ventricular fibrillation/tachicardia and early left ventricle aneurism. KaplanMeier survival curves demonstrated that incidence of cardiovascular death in AHF patients was higher in comparison with those without AHF at longterm followup (Figure 1). Conclusions: AHF is a frequent complication in STEMI even in patients with mrEF and is a powerful and independent predictor of 3year's survival. AHF patients had higher longterm risk, required special attention and monitoring during followup.